{"id":40574,"date":"2019-01-23T08:33:51","date_gmt":"2019-01-23T07:33:51","guid":{"rendered":"https:\/\/www.fedaiisf.it\/?p=40574"},"modified":"2019-01-23T19:40:09","modified_gmt":"2019-01-23T18:40:09","slug":"johnson-johnson-nuova-multa-pubblicita-ingannevole-di-una-protesi-difettosa","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/johnson-johnson-nuova-multa-pubblicita-ingannevole-di-una-protesi-difettosa\/","title":{"rendered":"Johnson &amp; Johnson. New fine. Misleading advertising of a defective prosthesis"},"content":{"rendered":"<h1><span class=\"tlid-translation translation\"><span class=\"\" title=\"\">Johnson &amp; Johnson to pay $120 million for false advertising<\/span><\/span><\/h1>\n<h3><span class=\"tlid-translation translation\"><span class=\"\" title=\"\">The pharmaceutical and its associate DePuy have been charged in the United States for the sale of a hip replacement that turned out to be defective.<\/span><\/span><\/h3>\n<p><a href=\"https:\/\/manufactura.mx\/quimica-y-farmaceutica\/2019\/01\/23\/johnson-johnson-pagara-120-mdp-por-publicidad-enganosa\" target=\"_blank\" rel=\"noopener\">January 23, 2019 \u2013 Manufactura<\/a><\/p>\n<p><span class=\"tlid-translation translation\"><span class=\"\" title=\"\">NEW YORK, USA \u2013 The American pharmaceutical group Johnson &amp; Johnson has reached an amicable agreement of 120 million dollars with some states of the country, to settle investigations into false advertising of defective hip replacements.<\/span><\/span><\/p>\n<p><span class=\"\" title=\"\"><a href=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/01\/protesi-JJ-difettosa_depuyasrhiprecalled.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-40576 alignright\" src=\"https:\/\/www.fedaiisf.it\/wp-content\/uploads\/2019\/01\/protesi-JJ-difettosa_depuyasrhiprecalled.jpg\" alt=\"\" width=\"270\" height=\"284\" \/><\/a>Letitia James, New York State Attorney General, said in a statement that the group and its partner DePuy misled the public about the longevity and purported quality of a prosthesis model.<\/span><\/p>\n<p><span title=\"\">\u201cWe shouldn&#039;t allow companies to mislead the public freely and especially when it comes to health issues,\u201d James said.<\/span><\/p>\n<p><span title=\"\">This agreement is &quot;an important message showing that misleading and deceptive medical practices will not be tolerated,&quot; the secretary added.<\/span><\/p>\n<p><span class=\"tlid-translation translation\"><span class=\"\" title=\"\">In addition to medicines and hygiene products, Johnson &amp; Johnson makes health care equipment and is currently the subject of complaints related to its talc in the United States.<\/span><\/span><\/p>\n<p><span class=\"\" title=\"\">Associated with DePuy Inc, Johnson &amp; Johnson marketed hip replacements that were returned when patients complained of severe pain and various complications.<\/span><\/p>\n<p><span class=\"\" title=\"\">Patients received either the ASR XL acetabular prosthesis or Pinnacle Ultamet between July 2003 and August 2010.<\/span><\/p>\n<p><span class=\"\" title=\"\">DePuy retired the ASR XL implants in 2010 and discontinued the Pinnacle implant in 2013.<\/span><\/p>\n<p><span title=\"\">Both companies have already signed agreements with associated plaintiffs and were asked on Monday to continue examining any requests from other interested parties.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>Johnson &amp; Johnson pagher\u00e0 120 milioni di dollari per pubblicit\u00e0 ingannevole La farmaceutica e la suo associata DePuy sono stati accusati negli Stati Uniti per la vendita di una protesi d&#8217;anca che si \u00e8 rivelata difettosa. enero 23, 2019 &#8211; Manufactura NEW YORK, USA &#8211; Il gruppo farmaceutico americano Johnson &amp; Johnson ha raggiunto un &hellip;<\/p>","protected":false},"author":4,"featured_media":35438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[41,22],"class_list":["post-40574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizie","tag-leggisentenze","tag-truffa-farmaci"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=40574"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/40574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/35438"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=40574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=40574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=40574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}